Close menu




Biotech

Photo credits: pixabay.com

Commented by Fabian Lorenz on September 2nd, 2025 | 07:50 CEST

INSIDER ALERT at Evotec! Valneva with new TARGET PRICE! Vidac Pharma stock soon to reach new ALL-TIME HIGH?

  • Biotechnology
  • Biotech
  • Pharma

Finally! Insiders are sending an important signal at Evotec. The stock has not yet reacted, but in the medium term, this could turn out to be a buy signal. Skepticism still prevails at present. Analysts are bullish on Vidac Pharma. In the fall of 2024, the biotech stock had multiplied in value. Is it now heading back toward its all-time high? According to analysts, significantly higher price gains are possible. Valneva, on the other hand, is not for the faint of heart. After doubling in price within a few weeks, the stock has plummeted again. Analysts recommend buying, but are significantly lowering their price target.

Read

Commented by Armin Schulz on September 2nd, 2025 | 07:25 CEST

After the price corrections: Is now the time for Novo Nordisk, Almonty Industries, and Puma?

  • Mining
  • Tungsten
  • Defense
  • Biotechnology
  • Sportswear

Volatile periods offer the greatest opportunities for savvy investors. While the masses are unsettled by price fluctuations, strategic investors have the chance to acquire fundamentally sound stocks at attractive prices. This discipline of keeping calm in the face of uncertainty separates the long-term winners from the losers. Three companies currently deserving of precisely this attention are Novo Nordisk, Almonty Industries, and Puma.

Read

Commented by Stefan Feulner on September 2nd, 2025 | 07:10 CEST

Bayer, BioNxt Solutions, FamiCord AG – Undiscovered gems with strong growth potential

  • Biotechnology
  • Biotech
  • Pharma
  • Medical
  • Technology

While artificial intelligence has been dominating the headlines for months and tech stocks are reaching record valuations, the biotech sector is leading a shadowy existence on the stock markets. Investors are shying away from the often complex and risky business models, with many stocks trading well below their all-time highs. However, while the spotlight is on AI, significant developments are taking place in the background: clinical trials are reaching key milestones, new therapeutic approaches, such as cell and gene therapies, are advancing, and partnerships with big pharma have increased substantially in recent years.

Read

Commented by Armin Schulz on August 28th, 2025 | 07:15 CEST

The BioNxt Solutions formula: How a simple idea can turn into a billion-dollar business – Without high risk

  • Biotechnology
  • Biotech

In the pharmaceutical industry, promising active ingredients often fail due to a simple problem, such as administration. Canadian biotech company BioNxt Solutions has taken on precisely this challenge. With a smart platform for oral dissolvable films and patches, the Vancouver-based innovator could not only make life easier for patients but also open up a lucrative growth opportunity for investors. We took a closer look at the promising technology behind it.

Read

Commented by Fabian Lorenz on August 27th, 2025 | 07:20 CEST

Quick 30% return possible? Novo Nordisk, D-Wave, and NetraMark shares!

  • Biotechnology
  • Biotech
  • AI
  • computing
  • hightech

Three completely different companies, but all with return potential: AI specialist NetraMark is on the verge of a technical breakout. NetraAI has outperformed ChatGPT and DeepSeek and is gaining more customers. If the breakout occurs, the stock could quickly move toward the analyst price target, representing a potential gain of around 30%. At Novo Nordisk, last week's price gains have almost been lost again. Wegovy's strong market entry in South Korea caused only brief jubilation. Now, competition from Eli Lilly is dampening the mood. At D-Wave, the stock could soon be heading toward new highs again. The Company plans to accelerate its growth in Asia, and new momentum for the stock is expected in September.

Read

Commented by André Will-Laudien on August 26th, 2025 | 07:20 CEST

Big moves! Buying frenzy at Novo Nordisk and PanGenomic Health, Valneva left behind

  • Healthcare
  • healthtech
  • Biotechnology
  • Biotech

Things are moving again in the biotech sector! While Novo Nordisk appears to have finally found its footing after three profit warnings, PanGenomic Health continues its upward trend. Since launching its new business model in May, the stock has staged a phenomenal rally of over 1,000%. Meanwhile, Valneva faces a major setback as the US Food and Drug Administration (FDA) has halted approval of the chikungunya vaccine Ixchiq due to severe side effects. This comes as a shock to investors, who are now waiting for the Company to provide further explanations. The stock market has reacted with a sharp drop in the share price. How can investors benefit from the current situation?

Read

Commented by Armin Schulz on August 26th, 2025 | 07:10 CEST

The blueprint for AI-driven drug discovery: How Evotec, NetraMark Holdings, and BioNTech are leveraging new opportunities

  • Biotechnology
  • Biotech
  • AI
  • Pharma

The pharmaceutical industry is undergoing a revolution. Artificial intelligence is reducing drug discovery times from years to months and dramatically increasing hit rates. Data-driven predictions and virtual simulations are increasingly replacing costly trial-and-error approaches. This technological leap is already generating concrete successes and massive competitive advantages for pioneers who implemented their digitalization strategies early on. Most recently, an AI-designed drug advanced to clinical trials in record time. Three companies driving this change and reaping its benefits are Evotec, NetraMark Holdings, and BioNTech.

Read

Commented by Fabian Lorenz on August 25th, 2025 | 07:25 CEST

A bombshell for takeover candidates! 100% share BioNxt Solutions leaves BioNTech and Co. behind!

  • Biotechnology
  • Biotech
  • Pharma

BioNxt shares have finally taken off. At the beginning of July, we last pointed out the opportunities offered by the Canadian-German life sciences company. Since then, the share price has risen by almost 100%, outperforming both the biotech index and investor favorites like BioNTech. However, this is likely to be just the beginning. In a conversation with the editorial team, management hinted at a strong news flow in the coming months. The Company is working flat out on its next-generation platforms to revolutionize drug delivery. For example, syringes and tablets are to be replaced by dissolvable films and transdermal patches. This not only makes BioNxt a prime acquisition candidate, but with a market capitalization of just CAD 100 million, the Company still appears to be anything but expensive.

Read

Commented by Nico Popp on August 25th, 2025 | 07:05 CEST

New research findings – Cell metabolism relevant in cancer: Roche, Novartis, and Vidac Pharma

  • Biotechnology
  • Biotech
  • Pharma
  • Cancer

What if cancer cells no longer grew uncontrollably, and we could target the metabolism of these cells directly? The so-called Warburg effect makes this possible. Discovered around 100 years ago by Otto Warburg, the effect describes the energy metabolism of cancer cells and shows that their metabolism differs from that of healthy cells. This opens up great opportunities for specific therapies in biotechnology. The theoretical assumption is that if the metabolism of cancer cells can be specifically disrupted, treatment will be targeted and free of side effects. Biotech start-up Vidac Pharma is fully committed to the Warburg effect. We explain what the Canadians are researching and why the technology could complement the offerings of several large pharmaceutical companies.

Read

Commented by Armin Schulz on August 21st, 2025 | 07:10 CEST

Overvaluations in pharma and biotech reduced – Novo Nordisk, BioNxt Solutions, and Bayer are NOW in focus

  • Biotechnology
  • Biotech
  • Pharma

Following the drastic market correction since the waning of the COVID-19 pandemic, the pharma and biotech sectors now offer more rationalized valuations and real opportunities. Instead of speculative hype, solid pipelines, clinical results, and disruptive technologies are what count today. Artificial intelligence is revolutionizing drug development, accelerating processes, and creating measurable competitive advantages. This new reality makes companies that are mastering their digital transformation particularly promising candidates. However, it is important to take a close look at each company. That is why we are examining three exciting companies today where there is a lot going on: Novo Nordisk, BioNxt Solutions, and Bayer.

Read